Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Dose-range Finding Study to Assess the Pharmacokinetic and Pharmacodynamic Parameters, Safety, Tolerability, and Immunogenicity of MAA868 in Patients With Atrial Fibrillation

NCT04213807 is registered in ClinicalTrials.gov with Anthos Therapeutics, Inc. as lead sponsor.

NCT NCT04213807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04213807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Dose-range Finding Study to Assess the Pharmacokinetic and Pharmacodynamic Parameters, Safety, Tolerability, and Immunogenicity of MAA868 in Patients With Atrial Fibrillation
Lead sponsor
Anthos Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 11, 2019
Completion date
March 8, 2021
Enrollment
28 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation